Search results for: decarboxylating
#38015561 2023/11/28 To Up
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma.Isocitrate dehydrogenase (IDH) enzymes catalyze the decarboxylation of isocitrate to alpha-ketoglutarate. IDH1/2 mutations preferentially convert αKG to R-2-hydroxyglutarate (R2HG), resulting in R2HG accumulation in tumor tissues. We investigated circulating 2-hydroxyglutate (2HG) as potential biomarkers for patients with IDH-mutant (IDHmt) cholangiocarcinoma (CCA). R2HG and S-2-hydroxyglutarate (S2HG) levels in blood and tumor tissues were analyzed in a discovery cohort of IDHmt glioma and CCA patients. Results were validated in cohorts of CCA and clear cell renal cell carcinoma (ccRCC) patients. The R2HG/S2HG ratio (rRS) was significantly elevated in tumor tissues, but not in blood for IDHmt glioma patients, while circulating rRS was elevated in IDHmt CCA patients. There were overlap distributions of circulating R2HG and total 2HG (t2HG) in both IDHmt and wild-type (IDHwt) CCA patients, while there was minimal overlap in rRS values between IDHmt and IDHwt CCA patients. Using the rRS cut-off value of 1.5, the sensitivity of rRS was 90% and specificity was 96.8%. Circulating rRS is significantly increased in IDHmt CCA patients compare to IDHwt CCA patients. Circulating rRS is a sensitive and specific surrogate biomarker for IDH1/2 mutations in CCA. It can potentially be used as a tool for monitoring IDH-targeted therapy.
Cha Len Lee, Grainne M O'Kane, Warren P Mason, Wen-Jiang Zhang, Pavlina Spiliopoulou, Aaron R Hansen, Robert C Grant, Jennifer J Knox, Tracy L Stockley, Gelareh Zadeh, Eric X Chen
2336 related Products with: Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma.100 assays50 assays100 assays96 Tests1 kit100 assays100 plates100 assays1 kit100 tests1,000 tests
#38014142 2023/11/13 To Up
COQ4 is required for the oxidative decarboxylation of the C1 carbon of Coenzyme Q in eukaryotic cells.Coenzyme Q (CoQ) is a redox lipid that fulfills critical functions in cellular bioenergetics and homeostasis. CoQ is synthesized by a multi-step pathway that involves several COQ proteins. Two steps of the eukaryotic pathway, the decarboxylation and hydroxylation of position C1, have remained uncharacterized. Here, we provide evidence that these two reactions occur in a single oxidative decarboxylation step catalyzed by COQ4. We demonstrate that COQ4 complements an strain deficient for C1 decarboxylation and hydroxylation and that COQ4 displays oxidative decarboxylation activity in the non-CoQ producer . Overall, our results substantiate that COQ4 contributes to CoQ biosynthesis, not only via its previously proposed structural role, but also via oxidative decarboxylation of CoQ precursors. These findings fill a major gap in the knowledge of eukaryotic CoQ biosynthesis, and shed new light on the pathophysiology of human primary CoQ deficiency due to mutations.
Ludovic Pelosi, Laura Morbiato, Arthur Burgardt, Fiorella Tonello, Abigail K Bartlett, Rachel M Guerra, Katayoun Kazemzadeh Ferizhendi, Maria Andrea Desbats, Bérengère Rascalou, Marco Marchi, Luis Vázquez-Fonseca, Caterina Agosto, Giuseppe Zanotti, Morgane Roger-Margueritat, María Alcázar-Fabra, Laura García-Corzo, Ana Sánchez-Cuesta, Plácido Navas, Gloria Brea-Calvo, Eva Trevisson, Volker F Wendisch, David J Pagliarini, Leonardo Salviati, Fabien Pierrel
2493 related Products with: COQ4 is required for the oxidative decarboxylation of the C1 carbon of Coenzyme Q in eukaryotic cells.100ug Lyophilized1 g100ug Lyophilized1100ug Lyophilized1 mg100ug Lyophilized100ug Lyophilized
#38014006 2023/11/16 To Up
harbors a hypoxia-responsive coproporphyrinogen dehydrogenase-like protein.is an apicomplexan parasite that is the cause of toxoplasmosis, a potentially lethal disease for immunocompromised individuals. During infection, the parasites encounter various growth environments, such as hypoxia. Therefore, the metabolic enzymes in the parasites must adapt to such changes to fulfill their nutritional requirements. can biosynthesize some nutrients, such as heme. The parasites heavily rely on their own heme production for intracellular survival. Notably, the antepenultimate step within this pathway is facilitated by coproporphyrinogen III oxidase (CPOX), which employs oxygen to convert coproporphyrinogen III to protoporphyrinogen IX through oxidative decarboxylation. Conversely, some bacteria can accomplish this conversion independently of oxygen through coproporphyrinogen dehydrogenase (CPDH). Genome analysis found a CPDH ortholog in . The mutant lacking CPOX displays significantly reduced growth, implying that TgCPDH potentially functions as an alternative enzyme to perform the same reaction as CPOX under low oxygen conditions. In this study, we demonstrated that TgCPDH exhibits coproporphyrinogen dehydrogenase activity by complementing it in a heme synthesis-deficient mutant. Additionally, we observed an increase in TgCPDH expression in when it grew under hypoxic conditions. However, deleting in both wildtype and heme-deficient parasites did not alter their intracellular growth under both ambient and low oxygen conditions. This research marks the first report of a coproporphyrinogen dehydrogenase-like protein in eukaryotic cells. Although TgCPDH responds to hypoxic conditions and possesses enzymatic activity, our findings suggest that it does not directly affect intracellular infection or the pathogenesis of parasites.
Melanie Key, Carlos Gustavo Baptista, Amy Bergmann, Katherine Floyd, Ira J Blader, Zhicheng Dou
2740 related Products with: harbors a hypoxia-responsive coproporphyrinogen dehydrogenase-like protein.000 U1 Set1 Set1 ml1 kit500100 μg100ug Lyophilized100ug Lyophilized100ug Lyophilized1 Set1 Set
#38013486 2023/11/28 To Up
Synthesis of unsymmetrical ketones dual catalysed cross-coupling of α,β-unsaturated carboxylic acids with aryldiazonium salts.A visible light-enabled synthesis of unsymmetrical ketones has been accomplished by the cross-coupling of α,β-unsaturated carboxylic acids and aryldiazonium salts embracing a synergistic eosin Y and Co(OAc)·4HO catalysis. The reaction involves decarboxylative aerobic CC bond cleavage, and is endowed with the creation of new C-C and C-O bonds with good substrate scope.
Shiv Chand, Anup Kumar Sharma, Anand Kumar Pandey, Krishna Nand Singh
1415 related Products with: Synthesis of unsymmetrical ketones dual catalysed cross-coupling of α,β-unsaturated carboxylic acids with aryldiazonium salts.5 G1 g250 mg1 kit 5 G430 tests5 mg50 ul100ug 500 G50 ug
#38013183 // To Up
[Identification of a new C-23 metabolite in sterol degradation of HGMS2 and analysis of its metabolic pathways].has the ability to produce steroidal intermediates known as 22-hydroxy-23, 24-bisnorchol-4-en-3-one (BA) upon the knockout of the genes for either the hydroxyacyl-CoA dehydrogenase (Hsd4A) or acyl-CoA thiolase (FadA5). In a previous study, we discovered a novel metabolite in the fermentation products when the gene was deleted. This research aims to elucidate the metabolic pathway of this metabolite through structural identification, homologous sequence analysis of the gene, phylogenetic tree analysis of . HGMS2, and gene knockout. Our findings revealed that the metabolite is a C23 metabolic intermediate, named 24-norchol-4-ene-3, 22-dione (designated as 3-OPD). It is formed when a thioesterase (TE) catalyzes the formation of a β-ketonic acid by removing CoA from the side chain of 3, 22-dioxo-25, 26-bisnorchol-4-ene-24-oyl CoA (22-O-BNC-CoA), followed by spontaneously undergoing decarboxylation. These results have the potential to contribute to the development of novel steroid intermediates.
Jianxin He, Xinlin Dong, Yongqi Huang, Shikui Song, Zhengding Su
1019 related Products with: [Identification of a new C-23 metabolite in sterol degradation of HGMS2 and analysis of its metabolic pathways].100 μg 5 G100 100 μg1 Set100 μg100 μg5 mg96 samples5mg1 module
#38011311 2023/11/27 To Up
Mild Approach to Nucleoside Analogues via Photoredox/Cu-Catalyzed Decarboxylative C-N Bond Formation. Total Synthesis of Oxetanocin A.The conventional -glycosylation methods for nucleoside synthesis usually require strongly acidic or basic conditions. Here we report the decarboxylative C(sp)-N coupling of glycosyl -hydroxyphthalimide esters with nucleobases via dual photoredox/Cu catalysis, which offered a mild approach to nucleoside analogues. A total synthesis of oxetanocin A, an antiviral natural product containing an oxetanose moiety, has been achieved by using this method.
Ruonan Wang, Hao Xu, Arpan Banerjee, Zhongwen Cui, Yuyong Ma, William G Whittingham, Peng Yang, Ang Li
1117 related Products with: Mild Approach to Nucleoside Analogues via Photoredox/Cu-Catalyzed Decarboxylative C-N Bond Formation. Total Synthesis of Oxetanocin A.9650 µg100ug/vial100 extractions 25 G1 kit(96 Wells)1 kitOne 96-Well Strip Micropl1 kit(96 Wells)480/kit
#38010740 2023/11/27 To Up
Stereoselective Synthesis of Tri- and Tetrasubstituted Allylsilanes via Copper-Catalyzed Decarboxylative Silylation of Vinylethylene Carbonates.Herein, a stereoselective copper-catalyzed decarboxylative silylation of readily available vinylethylene carbonates (VECs) with PhMeSi-Bpin is reported, affording a wide range of tri- and tetrasubstituted allylsilanes in moderate to high yields with -selectivity. This protocol was characterized by high stereoselectivity, broad substrate scope, operational simplicity, and mild reaction conditions, which were amenable to diverse derivatizations and gram-scale synthesis.
Wenzhu Ren, Yifei Yan, Yinhua Huang
2168 related Products with: Stereoselective Synthesis of Tri- and Tetrasubstituted Allylsilanes via Copper-Catalyzed Decarboxylative Silylation of Vinylethylene Carbonates.5 G 1 kit(s) 1000pcs100 ug/vial100ug10000 tests10μg/vial100ug/vial25 mg100 per bag, 10 bags per100 ug/vial
#38009806 2023/11/27 To Up
An UHPLC-QTOF-MS-based strategy for systematic profiling of chemical constituents and associated in vivo metabolites of a famous traditional Chinese medicine formula, Yinchenhao decoction.Yinchenhao decoction (YCHD), a famous traditional Chinese medicine formula, has been applied for relieving jaundice in China for more than 1800 years. However, the material basis for YCHD is still unclear, and the chemical composition and metabolism characteristic in vivo are undefined, making the potential effective constituents and mechanism of action unclear. Herein, an ultrahigh-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS)-based strategy was applied for the chemical profiling of YCHD, as well as their in vivo prototypes and global metabolites that defined the metabolome. Our results showed that a total of 139 chemicals were identified in YCHD, including 28 organic acids, 12 monoterpenoids, five diterpenes, three triterpenoids, 17 iridoids, 23 anthraquinones, 26 flavonoids, four coumarins and 21 other types. Moreover, 58 prototypes and 175 metabolites were found in rat biological samples after oral administration of YCHD; those distributed in plasma, liver, intestine and feces were suggested to be potentially effective substances. Oxidation, hydrogenation, decarboxylation and conjugations with methyl, sulfate and glucuronate were considered as the predominant metabolic pathways in vivo. In conclusion, this is a systemic study of chemical constituents and in vivo metabolome profiles of YCHD, contributing to the material basis understanding and further mechanism research.
Jing Wang, Bingchen Ouyang, Rui Cao, Yu Xu
2461 related Products with: An UHPLC-QTOF-MS-based strategy for systematic profiling of chemical constituents and associated in vivo metabolites of a famous traditional Chinese medicine formula, Yinchenhao decoction.1 ml48 samples100ug Lyophilized100 μg100 μg100 μg100.00 ug1 Set100 μg1 Set100
Error loading info... Pleas try again later.
#38007555 2023/11/25 To Up
Multi-omics analysis of hospital-acquired diarrhoeal patients reveals biomarkers of enterococcal proliferation and Clostridioides difficile infection.Hospital-acquired diarrhoea (HAD) is common, and often associated with gut microbiota and metabolome dysbiosis following antibiotic administration. Clostridioides difficile is the most significant antibiotic-associated diarrhoeal (AAD) pathogen, but less is known about the microbiota and metabolome associated with AAD and C. difficile infection (CDI) with contrasting antibiotic treatment. We characterised faecal microbiota and metabolome for 169 HAD patients (33 with CDI and 133 non-CDI) to determine dysbiosis biomarkers and gain insights into metabolic strategies C. difficile might use for gut colonisation. The specimen microbial community was analysed using 16 S rRNA gene amplicon sequencing, coupled with untargeted metabolite profiling using gas chromatography-mass spectrometry (GC-MS), and short-chain fatty acid (SCFA) profiling using GC-MS. AAD and CDI patients were associated with a spectrum of dysbiosis reflecting non-antibiotic, short-term, and extended-antibiotic treatment. Notably, extended antibiotic treatment was associated with enterococcal proliferation (mostly vancomycin-resistant Enterococcus faecium) coupled with putative biomarkers of enterococcal tyrosine decarboxylation. We also uncovered unrecognised metabolome dynamics associated with concomitant enterococcal proliferation and CDI, including biomarkers of Stickland fermentation and amino acid competition that could distinguish CDI from non-CDI patients. Here we show, candidate metabolic biomarkers for diagnostic development with possible implications for CDI and vancomycin-resistant enterococci (VRE) treatment.
Marijana Bosnjak, Avinash V Karpe, Thi Thu Hao Van, Despina Kotsanas, Grant A Jenkin, Samuel P Costello, Priscilla Johanesen, Robert J Moore, David J Beale, Yogitha N Srikhanta, Enzo A Palombo, Sarah Larcombe, Dena Lyras
1996 related Products with: Multi-omics analysis of hospital-acquired diarrhoeal patients reveals biomarkers of enterococcal proliferation and Clostridioides difficile infection.5 G100ug Lyophilized10 mg1 module1 module1 module0.5 mg
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia